The pharmaceutical market in Japan holds the second-largest position globally. To meet the healthcare demands of its population, Japan heavily depends on the import of pharmaceutical products. In order to leverage these opportunities, drug developers must adhere to the rigorous regulations set by the Pharmaceuticals and Medical Devices Agency (PMDA).
Richmond Pharmacology possesses the necessary expertise to assist you in bridging the gap for your upcoming Phase I clinical study.
A single centre study for Chiesi Pharmaceuticals. 16 Japanese and 16 Caucasian volunteers participated in cross over, bridging study for Chronic obstructive pulmonary disease. Read about our approach and the controls we introduced to reduce variability. Learn more here.
A cognitive function profile of a second generation antihistamine. The effect of rupatadine on cognitive functioning was evaluated by means of computerized cognitive tests: rapid visual information processing (RVP), reaction time (RT), spatial working memory (SWM) and visual analogue scales (VAS) with 27 Japanese volunteers. Learn more here.
We have conducted more than 100 ethnic bridging studies enabling us to build a trusted relationship with the PMDA.Read more +
Our recruitment database is the largest in Europe with more than 20,000 active 1st generation Japanese subjects.Read more +
We can accommodate studies with short-term and long-term residency periods.Read more +
Our expertise can help you accelerate your drug development timelines globally
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.